ERJ open research
Cure8 research brief
Why This Matters
People with COPD can have coexisting type‑2 inflammatory conditions, and those conditions become more common with higher blood eosinophil counts. Knowing this may influence clinicians’ attention to extra‑pulmonary T2 diseases and biomarker use.
Who Should Pay Attention
Clinicians treating COPD or asthma; researchers of T2 inflammation and biomarkers; adult patients curious about comorbid allergic and inflammatory conditions.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports a comparative analysis of type‑2 (T2) inflammatory comorbidities in people with COPD (without asthma) versus people with asthma, using a large UK primary‑care database (OPCRD).
The authors measured lifetime prevalence of several T2 conditions (allergic rhinitis, atopic dermatitis/eczema, nasal polyps, chronic rhinitis, eosinophilic oesophagitis, and ulcerative colitis) and examined how prevalence varied with blood eosinophil count (BEC).
They found T2 multimorbidities occur in COPD but are generally less common than in asthma; prevalence rose with higher BECs, especially for nasal polyps and ulcerative colitis. Eosinophilic oesophagitis was rare in both groups.
The study is database‑based and cross‑sectional in nature: it reports associations between diagnoses and blood eosinophil levels rather than proving causation. Details such as diagnostic criteria, timing of BEC measurement relative to diagnoses, and potential misclassification in electronic records may affect interpretation.
Keep In Mind
Based on the abstract from an observational database study (OPCRD); associations do not prove causation and may be affected by record coding and measurement timing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationERJ open research
AuthorsDavid M G Halpin, Jaspreet Kaur, Heath Heatley +6 more
InstitutionUniversity of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 1, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Conflict of interest: D.M.G. Halpin has received honoraria for lecturing, attending advisory boards and preparing educational materials from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Inogen, Menarini and Sanofi. J. Kaur, H. Heatley, F. Tyrer, C. Ariti and V. Carter are employees of the OPRI, UK. R. Pullen is an employee of the OPRI, Singapore. S. Pathak was an employee of the OPRI, UK. D. Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris and Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris and Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme and Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation Programme, and Health Technology Assessment; and he was an expert witness for GlaxoSmithKline.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood heavy metal and trace element levels in newly diagnosed cases of inflammatory bowel disease.
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...
Lipoprotein (a) and inflammatory bowel disease: a systematic review and meta-analysis.
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...
Impact of Zinc‐Dependent Enzymes on Zinc Deficiency and Inflammatory Response in Ulcerative Colitis
Zinc deficiency is common in UC, and this study suggests that changes in zinc‑dependent enzyme activity in the gut lining are linked with local inflammation. If confirmed, mucosal enzyme activity might help explain...